Discover the competitive landscape of Myelodysplastic Syndrome (MDS) therapeutics. With 498,757 cases in 2024 and a slight increase by 2029, the report reveals a robust pipeline of 262 molecules ...

By Denny Jacob. AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival.

Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies inspired by genetic resilience, today announced the completion of enrollment for its open-label Phase 2a ...

Roche, AbbVie say trial of Venclexta in patients with myelodysplastic syndromes falls short By Kevin Dunleavy Jun 16, 2025 4:23pm AbbVie Roche Venclexta (venetoclax) multiple myeloma ...

The myelodysplastic syndromes (MDS) are disorders of the haematopoietic stem cells in the bone marrow, that result in a decreased production of blood cells. MDS mainly affects patients aged 70 and ...

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona).

The Myelodysplastic syndromes group at the Josep Carreras Leukaemia Research Institute has enhanced the characterisation of the first cell model capable of faithfully representing this disease.

First-line luspatercept may offer significant advantages over erythropoiesis-stimulating agents (ESAs) for anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS), according to a ...

LEHI, Utah, June 4, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies inspired by genetic resilience, today announced the completion of ...

AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic ...

NORTH CHICAGO, Ill., June 16, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly ...

In the middle of what's been a never-seen-before public fallout between arguably two of the most powerful men in the world, US President Donald Trump said that billionaire Elon Musk was suffering ...